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ABSTRACT 
 
Different cell types have been employed in the search for a cellular therapy that is applicable 
for the treatment of heart failure. Remuscularization strategies using stem-cell-derived 
cardiomyocytes have been prone to arrhythmias. Mesenchymal stromal cells (MSCs) are one 
of the most promising cell types for the treatment of heart failure due to their diverse 
regenerative properties. We have isolated MSCs from the human fetal heart in the form of 
human fetal cardiac MSCs (hfcMSCs), which might comprise a more relevant cell source than 
bone marrow-derived MSCs, for the treatment of heart failure. Although the cell source is of 
importance for successful cell therapy, the efficacy of the cells also depends on avoiding 
anchorage-dependent apoptosis (anoikis) and immune rejection. Immune rejection may be 
counteracted with immunosuppressive drugs; however, these drugs generally have serious side 
effects that limit their suitability in cell therapy. We have used a transient blockade of T cell 
costimulation with the aim to induce immunologic tolerance through the generation of 
Regulatory T cells (Tregs) specifically for the antigens of the transplant. Anoikis may be 
diminished by the simultaneous administration of the exogenous extracellular matrix (ECM), 
which provides anchorage possibilities for the transplanted cells. 
In Paper I and II the use of costimulation blockade in xenogeneic and allogeneic mouse models 
was explored and we showed that Foxp3+ Tregs are associated with tolerated and viable grafts 
as well as reduced reactivity in mixed lymphocyte reaction tests. MSCs, known for their 
immunomodulatory properties, were shown to synergize with costimulation blockade to 
facilitate immunological tolerance to allogeneic insulin-producing islets in mice. 
In Paper III we showed that Matrigel synergizes with costimulation blockade to enable 
enhanced cell retention of hfcMSCs after subcutaneous implantation in mice. The hfcMSCs 
displayed vasculogenic potential in vivo, shown as the expression of CD31, and also the 
formation of vessel-like structures staining positive for laminin a4. In Paper IV, hfcMSCs were 
cultured on a 3D scaffold composed of a novel type of artificial spider silk, NT2RepCT, to 
conserve the cell connections and ECM at the time of implantation. The hfcMSCs displayed 
vasculogenic potential in the 3D cultures on NT2RepCT as well, with the formation of an ECM 
that stained positive for laminin a4 and fibronectin and contained vessel-like structures 
expressing CD31. After in vivo implantation, the hfcMSCs on the NT2RepCT were subjected 
to immune rejection regardless of costimulation blockade or isotype control treatment. 
In this thesis hfcMSCs were shown to have a vasculogenic potential as they also deposit 
laminins that are important for vascular structures and thereby may have the potential to prevent 
ischemic heart failure. We also demonstrated a synergistic effect between costimulation 
blockade and MSCs or Matrigel for enhanced cell retention. Artificial spider silk showed great 
potential for advanced in vitro studies with 3D cultures, but could not be used in vivo in its 
current form. 
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1 INTRODUCTION 
 
The loss of functional tissue due to cell death is a major component in the pathogenesis of 
several diseases. Offering a cure in the form of cell therapy, where the missing cell population 
is transplanted to the patient, has been, and remains, a developing area of research. Patients 
with diabetes mellitus type 1, a condition in which insulin-producing islet cells are destroyed, 
can receive new cells that are usually delivered through a catheter to the superior mesenteric 
vein1 – a kind of cell therapy. Heart disease is another area where cell therapy is of great 
interest. Heart failure affects about 2% of the population in the developed world2 and ischemic 
heart disease is a major cause of heart failure with reduced ejection fraction (EF)3. The abrupt 
loss of nutrients and oxygen when the blood supply is blocked during an ischemic event results 
in the remodeling of the myocardium, fibrosis and loss of function.4 There are medical 
treatments and devices, like cardiac resynchronization therapy (CRT), that may improve heart 
function;5 however, the prognosis has not improved in the last decade.6 Heart transplantation 
is the only potential cure for heart failure, though organ shortages and the adverse effects of 
immune suppressants pose serious limitations to its application. This has resulted in a treatment 
that is available only to a small group of patients and accompanied by severe comorbidities, 
such as opportunistic infections and kidney failure.  
In 2000, the first clinical trial of cell therapy for heart failure was performed using myoblasts.7 
Since then clinical trials with bone marrow cells,8 mesenchymal stromal cells9,10 and the cells 
of a cardiac progenitor profile11,12 have been conducted with the aim to improve heart function 
and reduce mortality for heart failure patients. Cellular therapy could be an option between 
medical treatment and heart transplantation offering the patient something approaching a cure, 
but at the same time increasing the availability of the treatment and decreasing the risks. 
However, even if the results from clinical trials with bone-marrow-derived cells indicate low 
risk to the patient,13 a meta-analysis from 2015 showed no convincing improvement in heart 
function.14 These negative results might be explained by the poor cell retention observed in 
both animal models15 and clinical trials,16 which is well illustrated in a syngeneic rat model that 
failed to show any relationship between the number of delivered cells and the number of 
engrafted cells at four weeks.17 Increasing cell survival after delivery is both important and 
difficult. Immune rejection and the loss of cell anchorage must be targeted and of course the 
appropriate cell source for a given condition has to be established. 
 
1.1 CELL SOURCE 
 
For the diabetic patient, it is evident that insulin-producing islets are lacking and the therapy 
should aim to replace them. In heart failure, the picture is more complex. Heart failure is often 
caused by ischemic heart disease,3 wherein the ischemia has resulted in a tissue defect and scar 
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formation. Heart tissue consists of muscle cells, supportive cells (cardiac fibroblasts) and 
vessels, forming a complex and important connection for normal heart function. The cell type 
or combination of cells that offers the best potential and feasibility needs to be carefully 
considered. 
1.1.1 Cardiomyocytes  
The obvious choice for cell therapy aiming to restore heart function is the delivery of cardiac 
muscle cells. These cells may be derived from human embryonic stem cells (HESCs) or 
induced pluripotent stem cells (iPSCs). Smaller animal models, including mice,18 rats19 or 
guinea pigs,20 have shown promising results with engrafted cardiomyocytes. However, when 
translated to non-human primates, ventricular arrhythmias were observed with HESC-derived 
cardiomyoctes21,22 as well as iPSC-derived allogeneic cardiomyocytes.23 In the aforementioned 
studies, xenogeneic or allogeneic cardiomyocytes coupled with the host cardiomyocytes, as 
visualized through a fluorescent calcium indicator (GCaMP2).24 The cardiomyocytes produced 
from HESCs and iPSCs were immature and likely differed in their conduction properties from 
host cardiomyocytes. This was illustrated by their reduced expression of connexin 43,25 which 
may comprise part of the explanation for the observed ventricular arrhythmias. 
Arrhythmogenesis is a major obstacle to any clinical application of cardiomyocyte-based 
cellular therapy. 
 
Figure 1. Cells of different origins have been utilized in the search for an effective cure for 
heart failure. Initially muscle cells, including skeletal myoblasts and cardiomyocytes (animal 
models), were used as replacement therapy. Cardiac progenitor cells have been hard to define 
and have been assumed to be more plastic. Mesenchymal stromal cell (MSC) therapy mainly 
aims to contribute to a local positive paracrine effect, enhancing the endogenous repair 
mechanisms. 
MSCs
Muscle cells
Cardiac progenitors
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1.1.2 Mesenchymal stromal cells 
MSCs were initially isolated from the bone marrow by Alexander Friedenstein in 1970.26 He 
found that when bone marrow cells were plated on a culture dish a portion of the cells would 
rapidly attach and these cells formed fibroblast-like cultures. Subsequently, these cells were 
found to form both bone and cartilage under certain conditions.27 Human MSCs were first 
characterized by Pittinger et al. in 199928 and have been retrieved from many different 
locations, including the adipose tissue.29 MSCs are considered to reside close to blood vessels 
and resemble pericytes,30 the cells that encapsulate smaller blood vessels and capillaries. 
According to the International Society for Cellular Therapy, MSCs should adhere to plastic 
culture dishes, express CD105, CD73 and CD90, lack CD45, CD34, CD11b or CD14, CD79a 
or CD19 and Human Leukocyte Antigen (HLA) DR expression and be able to differentiate into 
bone, cartilage and fat.31 MSCs are considered to exhibit immunomodulatory, pro-angiogenic 
and wound-healing properties.32 The immune modulation is achieved through both soluble 
factors and cell–cell interaction. This has been shown in experiments using transwell 
systems,33,34 and affects both the innate and the adaptive immune response. The 
immunomodulatory effect of MSCs is triggered by strong pro-inflammation through Tumor 
Necrosis Factor a (TNFa) and Interferon g (IFNg),35 which are mainly released by T cells and 
macrophages as a response to inflammatory stimuli. MSCs may then release a range of 
molecules that are important in immune modulation, including Indoleamine 2,3-Dioxygenase 
(IDO), Prostaglandin E2 (PGE2), Interleukin 10 (IL10), Transforming Growth Factor b 
(TGFb) and HLA-G5.36 
Macrophages may be divided into two subsets, M1 and M2, wherein M1 macrophages are pro-
inflammatory, producing IFNg and TNFa, and M2 macrophages are anti-inflammatory, 
producing IL-10 and promoting wound-healing.37 MSCs have been shown to skew the 
macrophages toward an M2 profile and PGE2 is essential for this function.38 The MSCs are 
believed to have a modulatory effect on the adaptive immune response, largely due to the 
suppression of T cell proliferation33,34 and the induction of regulatory T cells39 (Tregs) that 
promote immune tolerance.40 This process is performed in several steps, where MSCs first 
produce TGFb,36 which promotes Tregs’ induction from naïve CD4+ T cells.41 Secondly, 
MSCs release IDO in response to high levels of IFNg.35 IDO modulates dendritic cells (DCs), 
which are specialized antigen presenting cells (APCs), towards a tolerogenic profile, that 
induces Tregs.35,42 Thirdly, MSCs express HLA-G5, which induces Treg expansion.43 HLA-G 
is an isoform of the non-classical HLA molecule (low degree of genetic variance) found in the 
trophoblasts. HLA-G is tightly connected to immune tolerance towards the fetus during 
pregnancy, where Tregs are involved, and low levels of HLA-G are connected to preeclampsia 
and miscarriages.44 HLA-G5, along with PGE2 release, is also implicated in the suppressive 
effect of MSCs that is exerted on natural killer cells (NK cells),37,43 which are innate 
lymphocytes with cytotoxic properties activated by a lack of MHC-class I molecules. The 
major role of NK cells is to respond to tumors and virus infections, but they are also involved 
in the rejection of transplants. Taken together, in vitro observations indicate that MSCs react 
to strong inflammatory stimuli by producing factors that interfere with the inflammatory chain 
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reaction, which may otherwise cause excessive tissue damage. In response to mild 
inflammatory stimuli, MSCs react differently. When subjected to weak inflammatory stimuli, 
MSCs produce antibacterial peptides45 and promote inflammation mainly by recruiting and 
stimulating neutrophils.36,37 This dynamic response may implicate MSCs as an important part 
of our innate immune system, granting that the in vitro data is applicable to the in vivo situation.  
In 2000, MSCs were first used in a clinical trial.46 Patients with stage IV metastatic breast 
cancer received autologous MSC infusions along with hematopoietic stem cells to facilitate 
engraftment after myeloablative therapy. No adverse event related to the MSCs was observed. 
Subsequently, when theories of MSCs’ immunomodulatory potential have arisen, MSC-
infusions have been used successfully to treat severe graft-versus-host disease47,48 (GvHD) and 
acute respiratory distress syndrome49 (ARDS). The therapeutic effects observed are considered 
to relate to the paracrine factors described before as well as to the release of exosomes.50 GvHD 
and ARDS are conditions with misdirected overactive immunity, though the short-term 
immunomodulatory effect of MSCs seems to be enough to break the vicious inflammatory 
cycle, and cell engraftment or survival is not important in that context.  
 
             
 
Figure 2. A simplified overview of the response of MSCs to strong inflammatory stimuli, 
resulting in tolerogenic DCs, Treg induction, NK cell inhibition and an anti-inflammatory M2 
profile of macrophages. 
 
 
 
MSCIFNg
TNFa
DC
IDO
T cell
NKPGE2
HLAG5
TGFb
Macrophage M2
Treg
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MSCs are considered to have an almost exclusively paracrine function,51 and actual cell 
contribution to the tissue is not expected. However, whereas an intense effect for a short time 
is optimal for extreme inflammatory states, like GvHD and ARDS, the pathogenesis of heart 
failure is different. In considering an ischemic heart muscle with scarring and remodeling, it is 
reasonable to assume that a prolonged exposure to paracrine factors with pro-angiogenic and 
immunomodulatory activities would be optimal. Therefore, it is important to increase MSCs’ 
engraftment when considering them for the treatment of heart disease. It has been hard to 
evaluate MSC-engraftment in the human heart. Autopsy material from patients who received 
infusions of MSCs for various other conditions has shown a very low rate of engraftment.52 
Turning to animal models for a more precise answer yields conflicting results. Some studies 
show that MSCs survive long term after delivery to the heart without immune suppression, but 
in several of these experiments lipophilic dye or ferumoxide was used to label the cells.53,54 
These labels are not specific, since the dye is transferred to neighboring cells to a high extent55 
and the ferumoxide is accumulated in phagocytes, like macrophages,56 making the results hard 
to interpret. When other more robust methods, like GFP labeling or fluorescent in situ 
hybridization (FISH), were used to detect cells, no or very few MSCs were retained in the tissue 
a few weeks after transplantation.15,57,58 
1.1.3 Human fetal cardiac mesenchymal stromal cells 
The heart develops early during embryogenesis and a beating heart can be observed already in 
gestational week six. MSCs can be retrieved from fetal tissue and have been isolated from the 
human fetal heart.30,59 Fetal MSCs could be more advantageous to use in cell therapy due to 
their increased telomerase activity and increased proliferation rate.60 Cells originating from a 
first-trimester fetal heart differ from adult sources since these cells have the capacity to generate 
the components of the heart, including the endothelial cells, smooth muscle cells and, to a minor 
extent, cardiomyocytes in vitro.59 Due to their origin and potential to contribute to the different 
components of the heart, human fetal cardiac MSCs (hfcMSCs) may have a greater potential 
for cellular replacement therapy after a myocardial infarction. 
 
1.2 ANOIKIS 
 
1.2.1 Integrins, cadherins and the extracellular matrix 
As parts of a tissue, cells form bonds between themselves and neighboring cells as well as with 
the extracellular matrix (ECM). Many molecules participate in cell adhesion, with cadherins 
and integrins being of central importance. Cadherins mainly take part in cell–cell interaction61 
and integrins are involved in the formation of adhesive contacts between the ECM molecules 
and the cells.62 Both are transmembrane molecules with close links to the actin cytoskeleton.63 
Ligands binding to cadherins and integrins initiate the cellular pathways involved in 
proliferation,64 differentiation and migration and form complicated networks of interactions 
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between themselves that may be referred to as “adhesive crosstalk”.63 As this term indicates, 
cadherins and integrins participate in the communication between the cell and its surroundings. 
Cadherins also take part in the formation of the desmosome, which is connected to the 
intermediate filaments of the cell and confers the strong cell adhesions found in the skin and 
heart muscle.65  
Collagens, glycoproteins like laminins and fibronectin, and proteoglycans make up the ECM, 
which is a dynamic structure distributed throughout the organism with functions ranging from 
the construction of the mechanical milieu of an organ to its status as the reservoir of growth 
factors.66 Adhesion to the ECM is facilitated through the ligation of an ECM molecule to an 
integrin. The cellular response may enhance insulin release or angiogenesis, for example, 
depending on the ECM component, integrin and cell type involved.67,68 The ECM’s 
composition varies between organs and a lack of certain components may cause disease. For 
example, laminin a4 deficiency in mice has been shown to cause cardiomyopathy,69 which is 
likely mediated through difficulty establishing contact with blood-vessels.  
If connections between cadherins and integrins to other cells and the ECM molecules are 
missing, the cell will experience a loss of anchorage. In most cells, inactivated integrins or 
cadherins will fail to confer survival signals, stimulating apoptotic signaling instead.70,71 The 
loss of anchorage to the ECM and other cells may also cause apoptosis through Fas and Fas 
ligand upregulation, as well as Fas relocation when the cell changes shape due to different 
surroundings.71 The apoptosis, induced by the loss of anchorage, is usually referred to as 
anoikis and is considered to be a major reason for low cell survival and the loss of graft function 
in cell therapy. 
 
Figure 3. Illustration of the complex pathways involved in integrin and cadherin signaling. 
Proliferation, growth and survival of the cell is stimulated and apoptotic pathways are blocked 
through anchorage to other cells and the ECM by the ligation of integrins and cadherins. If 
these anchorage signals are missing, the blockage of apoptotic pathways is instead removed, 
which may result in anoikis. 
Grossman et al, Apoptosis, 2002 
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1.2.2 Strategies for cell delivery 
Injection of a single cell suspension is the common way to attempt cell implantation to the 
heart. To achieve this, cells are loosened from the culture plate using an enzymatic reaction 
that strips off adhesion molecules and thereby reduces their linkage capacity to other cells and 
the ECM. After this treatment, the cells are passed through a thin needle, increasing the risk of 
apoptosis, probably due to mechanical effects.72  
Insulin-producing islets meant for transplantation receive a similar treatment. They are infused 
through a thin catheter after retrieval from the pancreatic tissue, which is achieved through a 
collagenase treatment that digests the surrounding ECM.73 This treatment results in an 
increased loss of anchorage to the ECM after the implantation of the islet cells, which might 
cause anoikis and contribute to early graft loss. A small study conducted on Rhesus monkeys 
indicated improved islet survival when part of the ECM was kept or the anti-apoptotic molecule 
Bcl-2 was supplied,74 further supporting anoikis’ involvement in graft loss. Other ways to 
directly reduce anoikis through the addition of ECM components and anti-apoptotic agents 
have been successful in the transplantation of cardiomyocytes into the hearts of rats and 
macaques.19,21 The authors developed a pro-survival cocktail that included Matrigel, apoptosis 
inhibitor Bcl-XL and a caspase inhibitor. The work devoted to developing the techniques 
described above emphasizes the problem anoikis poses to any cell therapy in otherwise causing 
a low cell survival and engraftment. Among all the different methods developed to limit 
anoikis, one may identify two fundamentally different approaches: Cells are either mixed with 
ECM components before delivery or cells are delivered as a 3D structure, where cell–cell and 
cell–ECM interactions are conserved.  
1.2.3 ECM components to reduce anoikis 
The delivery of cells through a thin needle is technically easy and the anoikis induced by the 
single cell state,70,71 where integrins and cadherins lose their potential for ligation, may be 
avoided through the addition of a hydrogel or Matrigel to the cell suspension.19,75,76 Matrigel is 
frequently used for cell culture and has been shown to improve in vivo engraftment and the 
expression of integrins compared to PBS in a model of HESC-derived endothelial cells.77 
Matrigel consists of the ECM produced by chondrosarcoma cells, Engelbreth-Holm-Swarm 
(EHS), with a composition resembling that of basement membranes, including collagen IV and 
laminin 111, in addition to numerous growth factors.78 The positive effect of Matrigel on 
engraftment is likely due to the presence of these basement membrane proteins to which cells 
may form integrin connections and thereby avoid anoikis. Through its gelling properties, 
Matrigel will also restrict cell dispersion, and thereby increase the probability of cell–cell 
connections through cadherins, further decreasing the risk of anoikis. Basement membranes 
may vary in composition but collagen IV, perlecan and/or agrin (heparan sulfate 
proteoglycans), laminins and nidogens are always present.79  
Perlecan and other heparan sulfate proteoglycans sequester growth factors to the ECM, like 
TGFb and vascular endothelial growth factor (VEGF),79 which indicates that Matrigel, in 
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addition to inhibiting anoikis, serves as a reservoir for growth factors after its delivery to the 
tissue. Although there are many positive sides to Matrigel, its origin in mouse tumor cells and 
varying composition makes clinical use hard to imagine. In a clinical setting, hydrogels may 
be a better choice, but for in vitro and in vivo studies of animals where the importance of anoikis 
needs to be sorted out, Matrigel is still a valuable product.  
1.2.4 3D scaffolds to reduce anoikis 
An alternative to injecting or infusing cells could be the implantation of a 3D scaffold with 
cells attached. Implanting a 3D scaffold might be technically more advanced than injecting 
cells, but the advantages to engraftment could be immense, considering that the cell–cell and 
cell–ECM bonds that were established in the culture are conserved during implantation. 
Another advantage is the possible reduction of tissue damage and ischemia. Injection could 
cause ischemia by increasing the pressure in the tissue when cells are injected to the heart 
muscle. The infusion of insulin-producing islets, and possibly also other cells, causes graft-
ischemia when they are trapped in the venules of the liver.1 Ischemia attracts inflammatory 
cells, which may further increase the risk of apoptosis, necrosis and immune rejection. 
Scaffolds consisting of different hydrogels, fibrin or Matrigel have been studied in animal 
models with encouraging results.80-82  
An alternative to scaffolds that mimic the ECM is the use of spider-silk-based scaffolds for 3D 
culture and implantation. Spider silk is a material with the unique mechanical properties of 
extreme strength and high flexibility.83 It is composed of proteins with a mainly b-sheet 
structure, giving spider silk an amyloid-like configuration.84 A 3D scaffold composed of spider 
silk fibers would aim to provide a skeleton to support the generation of a new ECM by the 
cultured cells. This differs fundamentally from the other scaffolds discussed that provide ECM 
components to the cells.  
Originally, the most commonly used type of silk was derived from silkworms. Silkworm silk 
has been used by humans for centuries in clothing and later also in surgical sutures. However, 
native silkworm silk may cause allergic reactions and inflammation, probably due to the 
combination of sericin coating and fibroin core.85 Another type of silk fiber is produced by 
spiders and is stronger with a higher extensibility and stiffness than the silk produced by 
silkworms.83 However, spiders are territorial and therefore difficult to keep over time for the 
production of larger quantities of spider silk. To overcome this problem recombinant spider 
silk has been developed.  
Natural spider silk proteins (spidroins) are composed of non-repetitive C- and N-terminal 
domains flanking a repetitive region. These spidroins are generally about 3,000 to 4,000 amino 
acids residues long and are hard to efficiently express in bacteria.86 Stark et al. developed 
plasmids to express smaller units of the spidroin, which are still able to form silk-like structures 
in test tubes that are slowly tilted from side to side. According to their concept, one C-terminal 
domain (CT) is connected to four repetitive units (Rep), known as 4RepCT.87 Andersson et al. 
developed a novel miniature spidroin that includes the N-terminal domain (NT), 2 repeat units 
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and the C-terminal domain (NT2RepCT).88 NT2RepCT is far superior to 4RepCT in 
production yield and protein solubility and enables biomimetic spinning,88 as well as the 
generation of 3D structures. NT2RepCT has not been used in cell culture or in vivo, while 
4RepCT has been successfully used in both circumstances.89-93  
Native spider silk and other recombinant forms of spider silk have also been reported to support 
cell culture and in vivo implantation in animal studies.94-97 Generally, spider silk has been 
considered biocompatible and immune privileged.98 Macrophages have nonetheless been 
found surrounding implanted spider silk in several studies,91,95 and there have been indications 
of a more active immune reaction to native spider silk.94,99 However, the immune response to 
spider silk, including lymphocytic reactivity, has not been characterized thoroughly, leaving 
the question of spider silk’s immunogenicity unresolved.  
Figure 4. Illustration of the basic composition of the spider silk protein.  
 
1.3 IMMUNE TOLERANCE 
 
The history of organ transplantation between humans begins in 1954 with a kidney 
transplantation between identical twins.100 The first allogeneic human heart transplantation 
took place in 1967 and the patient survived 18 days, with the death attributed to acute 
rejection.101 Survival post-transplantation was initially very poor, often measured in months, 
due to immunological rejection.101,102 Immune tolerance was identified as the key to transplant 
success and experiments with total-body irradiation were performed, resulting in acceptance of 
the graft but also in the death of the patient due to bone-marrow aplasia.102 In the 60’s and 70’s, 
cortisone and azathioprine were used for immune suppression and in 1983, Cyclosporine A 
was introduced.103 Cyclosporine A revolutionized transplantation, improving the survival of 
renal grafts from 45% to 82% at two years.103 In 1994, FK506, also known as tacrolimus, came 
into clinical use. Cyclosporine A and tacrolimus use the same mechanism of action, inhibiting 
T cell proliferation through calcineurin inhibition.104 Calcineurin is a crucial element in 
enhancing the transcription of interleukin 2 (IL-2) in T cells, which is essential for T cell 
survival and proliferation after activation.105 Tacrolimus remains the basis of most 
immunosuppressive regimes and has beneficial effects on graft survival at the expense of 
severe side effects, however, including cancer, kidney failure, infections and cardiovascular 
disease.106 This has consequences for the usability of cell therapy for chronic diseases, like 
Rising et al., Nature Chemical Biology, 2015
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diabetes mellitus type 1 or heart failure, since the side effects of immune suppressive therapy 
will outweigh the advantages of a possible cure for most patients. A selective immune tolerance 
that leaves the immune response intact to respond to cancer cells and pathogens, while 
accepting transplanted cells, would be the optimal solution. This selective immune tolerance is 
the basic concept behind the studies where we induced immunological tolerance by using short-
term costimulation blockade. Before we discuss this concept, we need to address the different 
components of the immune response. 
1.3.1 Regulatory T cells 
The human immune system is divided into the innate and adaptive components. The adaptive 
immune cells, T cells and B cells recognize specific antigens through certain amino acid 
sequences that may bind to their receptor. The receptor is highly variable and the binding 
thereof induces the proliferation and production of cytokines, with the aim to kill presumed 
invaders. The innate immune system, including macrophages, complement and NK cells, may 
also recognize specific molecules, but they are not as dynamic, and generally respond to the 
command delivered by T cells in the form of cytokines. Since T cells are central both to the 
function and control of the immune system, their ability to separate “self” from “non-self” is 
normally implicated in an adequate or autoimmune response to a stimulus, even though other 
immune cells, like B cells and macrophages, may actually bring about the event.  
Thymic selection is a process where, among other things, the T cells’ ability to bind self-
antigens is assessed. T cells binding self-antigens are deleted or directed toward a tolerogenic 
profile.107 Tolerogenic T cells, Tregs, mediate their effect through both cell–cell interaction and 
cytokine production.108 Most Tregs are CD4+ cells that acquire their profile in the thymus.107,109 
However, Tregs may also be generated from naïve CD4+ T cells in response to the ligation of 
the T cell receptor when other inflammatory stimuli are not present.110 
Tregs were initially identified in 1995 as CD4+ T cells expressing CD25,111 a subunit of the IL-
2 receptor. A few years later, a mutation of the transcription factor forkhead box 3 (Foxp3) was 
found to be the reason for the severe autoimmune disorder Immune Dysregulation, 
Polyendocrinopathy, Enteropathy, X-linked (IPEX).112 Foxp3 has since then been identified as 
the central element in the development of a tolerogenic profile in T cells.113 IPEX is the 
consequence of Treg depletion and resembles the phenotype of severe GvHD or graft rejection, 
but directed to the patient’s own body.114  
1.3.2 T cell costimulation 
As described above, T cells are activated after binding their specific antigen. However, antigen 
binding is not adequate for T cell activation and a second signal through costimulatory 
molecules is essential.115 For costimulation to take place, the DC and T cell must interact 
closely and the CD4+ T cell must recognize its antigen presented on the Major 
Histocompatibility Complex (MHC) class II molecule of the DC. After this interaction, there 
are two main outcomes. If inflammatory stimuli are present, for example, toll-like receptor 
(TLR) ligation or inflammatory cytokines, the DC expresses costimulatory molecules, most 
  11 
importantly CD80/86, which bind CD28 on the T cell. Successful costimulation results in a 
mature effector T cell. In the second scenario costimulatory molecules are absent on the DC, 
generally due to a non-inflammatory environment, and this may induce anergic T cells or T 
cell development into a Foxp3+ Treg.116 The need for an inflammatory environment as well as 
T cell antigen recognition for the generation of effector T cells may protect against 
inappropriate T cell activation and autoimmunity.  
Kinnear et al. Transplantation 2013 
Figure 5. An overview of important molecules in the costimulation of T cells. Both negative 
and positive signals are involved, resulting in the initiation or inhibition of overlapping 
pathways of importance for cell proliferation and cytokine production. 
 
There are several different costimulatory molecules that are important in T cell activation one 
way or the other, wherein CD80/86-CD28 and CD40-CD40L, along with the formation of a 
functional immunologic synapse for DC – T cell interaction, can be viewed as central and will 
be further discussed in the following paragraphs. 
1.3.3 CTLA4Ig 
The CD28 receptor on the T cell is essential to costimulation. When the T cell receptor is 
ligated, CD28 will bind CD80/86 on the DC and a strong proliferative signal is initiated within 
the T cell, resulting in increased IL-2 production.115 Simultaneously, a negative feed-back loop 
is activated where cytotoxic T-lymphocyte-associated protein 4 (CTLA4) is brought to the 
surface of the T cell. CTLA4 also binds CD80/86, but with higher affinity than CD28117 and 
inhibits prolonged proliferation by removing CD80/86 from the DC surface through 
endocytosis, thereby blocking further costimulation.118 CTLA4 is also expressed by Tregs and 
is essential for tolerance induction119 through the removal of costimulatory molecules and 
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possibly also through the induction of IDO expression and other tolerogenic pathways in 
DCs.108  
In searching for alternatives to using calcineurin inhibitors as immunosuppressive treatment 
agents, a fusion protein consisting of the extracellular domain of CTLA4 and the Fc region of 
a human Immunoglobulin G1 (IgG1) molecule, CTLA4Ig, was created. The aim was to block 
T cell costimulation and thereby avoid the rejection of transplanted organs by inducing T cells 
that were anergic and/or tolerogenic toward the alloantigens derived from the donor. The first 
version, abatacept, was further refined into belatacept, with enhanced affinity for CD80/86.120 
Belatacept has been used as a substitute for tacrolimus in kidney transplantation with reduced 
nephrotoxicity and a better cardiovascular profile at the cost, however, of an increased risk of 
acute rejection.121 Belatacept has also been evaluated for liver transplantation, giving rise to an 
increased risk of graft loss and mortality and resulting in the termination of the clinical trial.122 
Today, belatacept is mainly considered for kidney transplant patients who are afflicted by the 
side effects related to tacrolimus and there are few clinical trials with belatacept concerning the 
transplantation of other organs.123 The increased acute rejection has been attributed to CD28- 
T cells, independent of costimulation through the interaction of CD28 and CD80/86. CD28- T 
cells are not present at birth, but are found to increase with age in humans.124 CD8+CD28-  T 
cells are frequently occurring and include regulatory T cells,125 whereas the CD4+CD28- T cell 
population is less common and accumulates in inflammatory disorders.126 The latter seem to 
make up a senescent T cell population, which is often involved in autoimmunity.127 These 
CD4+CD28- T cells are likely to increase the risk of belatacept-resistant rejection, as it has been 
shown that accumulation of a subset of these cells will increase the risk of kidney transplant 
rejection in patients on belatacept but not tacrolimus treatment.128  
1.3.4 Anti-CD40L 
While the costimulatory molecule CD28 is constitutively expressed by naïve T cells, CD40L 
is induced when the T cell binds its ligand. Mature DCs, exposed to inflammatory stimuli, 
express CD40, which binds CD40L, resulting in both enhanced T cell proliferation and the 
stimulation of the DC to produce proinflammatory cytokines.129 The antibody-mediated 
blockade of CD40L was initially promising with successful animal experiments, including an 
allogeneic kidney transplant model in non-human primates.130 where anti-CD40L alone was 
enough to induce acceptance. In theory, anti-CD40L may work through a dual mechanism with 
both direct blockage of T cell activation and selective depletion of activated T cells by antibody 
labeling, which may account for the efficiency observed. CD40L is also present in a soluble 
form and may be secreted by thrombocytes, where it is involved in the formation of a stable 
thrombus.131 Thrombotic events using anti-CD40L were initially reported in non-human 
primates132 and subsequently, in humans when a clinical trial conducted in 2003 with systemic 
lupus erythematosus (SLE) patients was interrupted for this reason.133 The likely mechanism 
was anti-CD40L-mediated thrombi destabilization, causing embolus, and the binding of anti-
CD40L to activated thrombocytes.131 Activated thrombocytes display CD40L on their surface 
and the Fc part of anti-CD40L may bind other thrombocytes, causing aggregation. Since the 
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recognition of the thrombotic side effects of anti-CD40L, CD40 antibodies have been 
developed and tested in animal models of transplantation with mixed results.134,135 Some of the 
effects observed with anti-CD40L could have been lost due to the loss of the antibody-mediated 
destruction of activated T cells. 
1.3.5 Anti-LFA-1 
The integrin lymphocyte function-associated antigen 1 (LFA-1) is important in the adhesion of 
immune cells, for example, in their migration from the blood stream to target tissues. LFA-1 is 
also implicated in T cell costimulation, where it binds intercellular adhesion molecule 1 
(ICAM-1) to establish the immunologic synapse.136 This is essential for the tight interaction 
needed between the DC and T cell for T cell activation.137 Antibodies directed towards LFA-1 
have been effective in the treatment of autoimmune disease and in 2003, efalizumab was 
approved for the treatment of psoriasis. In 2009, it was withdrawn when several patients 
developed progressive multifocal leukoencephalopathy (PML) a disease that affects 
profoundly immune compromised individuals due to the reactivation of the John Cunningham 
(JC) virus.138 
PML is also associated with treatment with monoclonal antibodies directed toward the very 
late antigen 4 (VLA-4), natalizumab, which is used for the treatment of multiple sclerosis.139 
VLA-4 is also an integrin that is important in lymphocyte adhesion, demonstrating the 
significance of adhesion in immune cell function and also the potency of these drugs. 
1.3.6 Costimulation blockade 
As described above, the blockade of costimulatory molecules has been investigated for the 
treatment of autoimmune disease and transplantation with mixed results. It is generally 
effective, but as with other immune suppressants, the long-term side effects may be severe. The 
initial hope was that costimulation blockade would be able to mimic the natural tolerance to 
self-antigens and extend this tolerance to transplanted cells through the selective induction of 
Tregs. In theory, the total blockade of costimulation at the time of transplantation may induce 
Tregs specific to transplant-derived peptides. The blockade should be administered transiently 
and the Tregs specific to the transplant would confer indefinite and specific tolerance, without 
further immune suppression. This would constitute an entirely new way to address rejection, 
wherein long-term immune suppression could be avoided.  
For allogeneic transplantation in mice, transient costimulation blockade combining CTLA4Ig 
and anti-CD40L have been effective in some settings,140 but more stringent immunological 
models have revealed that graft survival is not indefinite.141 The addition of anti-LFA-1 has 
been shown to facilitate xenograft survival in mice, including HESCs, when combined with 
CTLA4Ig and anti-CD40L.142-144 However, when translated to non-human primates, long-term 
allograft survival (years) with short-term costimulation blockade has not been achieved.145-147 
The more complex immune system of primates and their longer life-span, along with exposure 
to different antigens and infections, may explain these observations. Infections increase the risk 
of heteroimmunity, meaning the pre-existence of memory cells specific to the transplant, due 
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to similar antigens on the pathogen and transplant. Further studies are needed to better 
understand the mechanisms behind the prolonged graft survival achieved with transient 
costimulation blockade in animal models. 
 
 
Figure 6. Schematic overview of how a costimulation blockade may interrupt the interaction 
between a T cell and a DC. 
 
In this doctoral thesis I have considered different ways to enhance cell retention in the tissue. 
Costimulation blockade, CTLA4Ig and anti-CD40L with or without anti-LFA-1 were used to 
avoid rejection without continuous immune suppression. Matrigel or a new kind of artificial 
spider silk, NT2RepCT, supplied anchorage for the cells to avoid anoikis. In the first two 
papers, the immune reaction was studied both histologically and functionally and in the last 
two papers, strategies to avoid anoikis were combined with costimulation blockade to enhance 
engraftment. 
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2 AIMS 
 
The overall aim of this thesis was to identify and explore methods to improve cell engraftment 
in xenogeneic and allogeneic cell transplantation. The specific aims of the studies included are 
stated below. 
 
STUDY 
I. To further explore the possibilities and mechanisms for the acceptance of human 
embryonic stem cells in mice with the use of CTLA4Ig, anti-CD40L and anti-LFA-1. 
II. To investigate the synergistic effects of MSCs and costimulation blockade on graft 
acceptance in an allogeneic animal model. 
III. To investigate in vivo retention and the vasculogenic potential of xenogeneic human 
fetal cardiac MSCs in the subcutaneous tissue of mice after a transient course of 
CTLA4Ig, anti-CD40L and anti-LFA-1 treatment. 
IV. To explore the biocompatibility of NT2RepCT when it is used as a 3D scaffold for 
human fetal cardiac MSCs in vitro and in vivo. 
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3 MATERIALS AND METHODS 
 
3.1 ETHICAL APPROVAL 
Human fetal tissue was obtained after the donor’s informed consent and approval by the 
Regional Ethics Board in Stockholm, 2013/457-31/4 and 2015/1369-31/2 (paper III and IV). 
All animal experiments were approved by the Linköping Ethical Committee on Animal 
Experiments with ethical approval numbers S198-11 and S31-12 (Paper I), S 76-11 and S16-
13 (Paper II) and S31-14 and S22-15 (Paper III and IV). 
 
3.2 2D CELL CULTURE AND CELL EXPANSION (PAPER III AND IV) 
The hfcMSCs were isolated through the collagenase digestion of fetal heart tissue in week 6 to 
10. The cells were seeded onto plastic culture dishes and the adherent cells, the mesenchymal 
fraction, were kept and expanded on Geltrex-coated culture plates in DMEM/F12 supplied with 
2% fetal bovine serum (FBS) and B27 as well as 100ng/ml Wnt3a and 10ng/ml Epidermal 
Growth Factor (EGF). At passages 6 to 10, the cells were analyzed or used in experiments. The 
hfcMSCs were characterized earlier and fulfill the criteria for MSCs established by the 
International Society for Cellular Therapy (ISCT).59 
After expansion, the cells were re-seeded in culture dishes either straight onto the cell-culture-
treated plastic surface or onto dishes coated with Geltrex or NT2repCT. The cells were given 
DMEM/F12 supplied with 2% FBS and B27. After five days, the cells were removed from the 
culture dish and counted using Trypan blue 0.4% and automated cell counter CountessÒ 
(Thermo Fisher Scientific). Cell death was assessed in the culture dish with Propidium Iodine 
(PI) staining and the number of dead cells per well was estimated using a fluorescence 
microscope. 
 
3.3 MATRIGEL 3D CULTURES (PAPER III) 
The hfcMSCs in DMEM/F12 were mixed with Matrigel Matrix at a 1:1 ratio to produce a 
suspension with 2,000 cells/µl. Fifty µl was seeded as a hanging drop and allowed to 
polymerize. After 10 days, the 3D cultures were used for further analysis. 
 
3.4 ARTIFICIAL SPIDER SILK SCAFFOLDS WITH 3D CULTURES (PAPER IV) 
Thin NT2repCT fibers were modeled into 3D structures, referred to as fiber nests. The fiber 
nests were divided into pieces, or scaffolds, with a diameter of approximately 5 mm to make 
implantation feasible. The scaffolds were placed at the bottom of a non-adhesive test tube, 
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which restricted the attachment of the cells to the NT2RepCT scaffold. The hfcMSCs were 
seeded on top of the scaffold and DMEM/F12 supplied with 2% FBS and B27 or endothelial 
differentiation medium (Lonza) was added. The 3D cultures were harvested at 2 weeks for in 
vivo implantation. The 3D cultures dedicated to in vitro analyses were snap-frozen in Optimal 
Cutting Temperature compound (OCT) at 2 to 8 weeks. 
 
3.5 ANIMAL EXPERIMENTS  
All mice were purchased from Scanbur or Taconic Biosciences.  
For Paper I Nod Scid Gamma (NSG), Scid/Beige, C57bl/6 and Balb/C mice were used. The 
mice were anaesthetized with continuous isoflurane and (3-5) x 106 HESCs re-suspended in 
PBS were injected under the kidney capsule. 
For Paper II C57bl/6 and Balb/C mice were used. The C57bl/6 mice were rendered diabetic by 
75 mg/kg Alloxan treatment. Allogeneic insulin producing islets were delivered through the 
portal vein alone or together with autologous MSCs. The mice were given either CTLA4Ig 
alone, CTLA4Ig with anti-CD40L or isotype control antibodies (human IgG and hamster IgG) 
as an intraperitoneal injection on the day of transplantation (d0) and every other day until 
postoperative day 10. 
For Paper III, NMRI mice were implanted with hfcMSCs as a subcutaneous injection behind 
the ear. The cells were re-suspended in Matrigel or DMEM/F12. Continuous isoflurane was 
used to anaesthetize the mice during the procedure.  
For Paper IV, NMRI mice were implanted with NT2repCT 3D scaffolds with or without 
hfcMSCs cultures attached. The mice were anaesthetized with continuous isoflurane and an 
incision behind the ear was made where the 3D culture could be inserted into the subcutaneous 
fat. One or two stitches were used to close the wound.  
All immunocompetent mice that were implanted with human cells (Paper I, III, IV) received a 
combination of CTLA4Ig, anti-CD40L and anti-LFA-1 or isotype control antibodies (human 
Fc-IgG1, hamster IgG and rat IgG2a) as an intraperitoneal injection on the day of 
transplantation and every other day until postoperative day 6.   
All mice were euthanized through neck dislocation and kidney (Paper I), liver (Paper II) or 
subcutaneous grafts (Paper III and IV) that were excised, embedded in OCT and snap-frozen. 
When a mixed lymphocyte reaction was performed the spleen was also harvested.  
 
3.6 MIXED LYMPHOCYTE REACTION (PAPER II AND III) 
The mixed lymphocyte reaction (MLR) was performed to further evaluate whether 
costimulation blockade induced immunologic tolerance. The same method was also used to 
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validate the quality of the costimulation blockade antibodies when a new batch was obtained 
(Paper III).  Irradiated splenocytes from naïve Balb/C mice were used as stimulators. The 
C57bl/6 naïve splenocytes or splenocytes from animals in different treatment groups (Paper II) 
were used as responders. Stimulator and responder splenocytes were co-cultured for 3 days and 
subsequently pulsed with [H3] thymidine. After 18 h, radioactive incorporation was counted to 
estimate the number of cell divisions. When MLR was applied to test the costimulation 
blockade antibodies, the antibodies were added to the coculture to verify their inhibitory effect. 
 
3.7 FLUORESCENT IN SITU HYBRIDIZATION (FISH) (PAPER I, III AND IV) 
The cryo-sections were stained with hematoxylin and eosin (H&E) to localize the area of 
injection or the NT2repCT scaffold. Sections close to or within possible grafts were fixed in 
4% formaldehyde and antigen retrieval was performed by boiling the tissue sections in citric 
buffer. The slides were subsequently digested with pepsin (100µg/ml) in 0.01M HCl at 37°C 
and the hybridization probe (07J04-005, Abbot) was added, after which the slides were heated 
to 74°C to achieve hybridization. The slides were incubated over night at 37°C and then washed 
in saline-sodium citrate (SSC) buffer with 0.3% Igepal at 72°C before they were dried and 
stained with 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI) or subsequently used for 
immunohistochemistry.  
 
3.8 IMMUNOHISTOCHEMISTRY 
Snap-frozen tissue or 3D cultures in OCT were sectioned into 5 µm sections. For Aggrecan 
staining, paraffin embedded cell-clusters were used. The tissue sections were fixed in either 
4% formaldehyde in PBS, cold ethanol or cold acetone. Antigen retrieval was performed when 
necessary either by treating the slides with 0.3% Triton in PBS or Heat Induced Antigen 
Retrieval (HIER), which we achieved by boiling the slides in citric buffer. Primary antibodies 
against CD4 (YTS191.1), CD8 (KT15), Foxp3 (FJK-16S), CD31 (JC70A and polyclonal 
rabbit), aSMA (1A4 or polyclonal rabbit), Troponin T (1C11), Vinculin (hVIN-1), Collagen 
IV (polyclonal rabbit), Perlecan (A71), Laminin g1 (2E8), Laminin a4 (CL3183 and polyclonal 
rabbit), Laminin a5 (polyclonal rabbit), Fibronectin (polyclonal rabbit) and Aggrecan (AF-28) 
were used. Secondary antibodies goat anti-Rabbit IgG (AF488), rabbit anti-Mouse IgG 
(AF488), donkey anti-Rat IgG (AF488) or donkey anti-Rabbit IgG (AF546) were chosen 
depending on the origin of the primary antibody. 
Immunohistochemical staining was also performed on cells and Matrigel 3D cultures fixed in 
the culture dish. The presence of CD31, aSMA or Troponin T was assessed using the 
antibodies listed above.  
 
 20 
3.9 TAQMAN PCR (PAPER III) 
The hfcMSCs were harvested after expansion to assess mRNA expression. Commercially 
available Human Aortic Endothelial Cells (HAEC) and Human Carotid Artery Smooth Muscle 
Cells (HCtASMC) were analyzed together with hfcMSCs as a control and for comparison.  
A Pico Pure RNA Isolation kit was used to extract RNA from the cells and a High Capacity 
cDNA Reverse Transcription kit was used to produce cDNA. Gene assays for CD31 (Platelet 
Endothelial Cell Adhesion Molecule – PECAM1), aSMA (ACTA2) Troponin T (TNNT2) and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used in the PCR reactions. To 
calculate the ratio between the gene of interest and the endogenous control (GAPDH), we used 
the comparative DCt method. 
 
3.10 STATISTICAL ANALYSIS 
For Paper II, one-way analysis of variance followed by the Tukey-Kramer post hoc test was 
applied to analyze the data. The Kaplan-Meier method was used to visualize animal survival 
and the log-rank test was used for comparisons between the treatment groups. 
For Paper III and IV, the Kruskall Wallis test with Dunn’s correction for multiple comparisons 
was used when analyzing ³ 3 groups and the Mann-Whitney U-test was used for 2 groups.  
The value of p<0.05 was considered to indicate a significant difference. 
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4 SUMMARY OF RESULTS 
 
4.1 PAPER I AND II – IMMUNOLOGY 
 
4.1.1 Costimulation blockade allows HESC engraftment in mice (Paper I) 
Immunocompetent mice, Balb/C and C57bl/6, along with immunodeficient mice, Scid/beige 
and NSG, were transplanted with HESC line HS181 under the kidney capsule (Table 1). After 
6 to 8 weeks the presence of human cells was assessed using FISH that identified human DNA. 
NSG mice are severely immunodeficient and lack both adaptive and innate immune functions, 
including functional NK cells, and are known to accept human cells148. These mice were used 
as a positive control, where two out of two mice accepted HS181 and displayed large teratoma-
like grafts, establishing the model as feasible. The immunocompetent mice and Scid/beige mice 
were subsequently transplanted with HS181 and treated with CTLA4Ig, anti-CD40L and anti-
LFA-1 (costimulation blockade) or isotype control antibodies every other day during the first 
week after transplantation. Scid/beige mice were included due to their immunodeficiency to 
ensure that the antibodies did not interfere with engraftment and to ascertain cell viability. 
Scid/beige mice lack adaptive immunity but display functional NK cells.149 To our surprise, 
none of the Scid/beige mice accepted HESCs; instead 3 out of 12 immunocompetent mice 
treated with costimulation blockade did. The engrafted HESCs formed teratoma-like structures, 
similar to what was seen in the NSG mice. The immunocompetent mice treated with isotype 
control antibodies served as negative controls and no surviving HESCs were identified in these 
animals, which agrees with the findings of earlier studies.144  
                                            
Table 1. Human embryonic stem cells transplanted into different mouse strains. 
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In order to further support our findings a different HESC line, HS360, was transplanted to 
immunocompetent mice. Two out of two mice treated with costimulation blockade displayed 
surviving human cells. The mice treated with isotype control antibodies rejected HS360. 
 
4.1.2 Costimulation blockade and MSCs synergize for survival of allogeneic 
islets in mice (Paper II) 
To study whether allograft survival in mice may be improved by combining CTLA4Ig and 
anti-CD40L with MSCs, a diabetic mouse model was used. The C57bl/6 mice were rendered 
diabetic and given insulin-producing islets of Balb/C origin. The islets were injected to the liver 
via the portal vein with or without autologous MSCs. The mice were treated with CTLA4Ig, 
CTLA4Ig + anti-CD40L or isotype control antibodies (Table 2). The blood glucose levels were 
measured daily, and two 2 consecutive days showing a glucose level >20 mM was considered 
a rejection.  
MSCs combined with CTLA4Ig and anti-CD40L significantly increased graft survival, in 
comparison to all other groups, to > 100 days for every recipient (Fig. 7A). Thirty days after 
transplantation, a glucose tolerance test was performed to test graft function. This demonstrated 
that mice treated with MSCs, CTLA4Ig and anti-CD40L had blood glucose levels equivalent 
to non-diabetic mice at 90 min post-exposure, with glucose levels significantly lower than those 
of mice treated with only costimulation blockade (Fig. 7B). Insulin mRNA in the liver of 
recipients treated with MSCs, CTLA4Ig and anti-CD40L was found to decrease at 100 days 
post-transplantation compared to at 30 days, but was still significantly higher than for the other 
treatment groups. 
 
Table 2. Experimental groups and islet graft survival. 
 
4.1.3 Foxp3+ T cells surround surviving allogeneic and xenogeneic cells in 
immunologically tolerant mice (Paper I and II) 
To understand the nature of immunologic acceptance of the allogeneic and xenogeneic grafts 
described above, tissue sections from recipients with surviving grafts were stained for CD4, 
CD8 and Foxp3. In study II, allogeneic islets were engrafted in the mice treated with MSCs, 
CTLA4Ig and anti-CD40L and in study I, the xenografts of HESCs survived under the kidney 
capsule in costimulation-blockade-treated animals. A similar finding in both studies, was that 
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the allo- and xenografts were surrounded by Foxp3+ cells at the border between the graft and 
the host. Treatment with only CTLA4Ig and anti-CD40L resulted in allografts being more 
scarce in Foxp3+ cells and CD4/CD8 infiltration dominated. 
 
4.1.4 TGFb mRNA is increased in the liver of mice with engrafted allogeneic 
islets at 100 days (Paper II) 
TGFb, IDO and Foxp3 mRNA levels were assessed in the liver of allogeneic islet recipients to 
further analyze the immunologic response to the surviving grafts. TGFb is a cytokine with 
immunosuppressive properties and is associated with Treg transformation. TGFb mRNA was 
upregulated in all animals with surviving islets at 100 days post-transplantation when compared 
to 30 days post-transplantation.  
IDO is an immunomodulatory molecule produced by MSCs37 and tolerogenic DCs42 as a 
response to inflammation. IDO mRNA was measured 100 days after transplantation and found 
in recipients treated with MSCs, CTLA4Ig and anti-CD40L or CTLA4Ig and anti-CD40L with 
no significant difference. The other groups displayed very low IDO mRNA levels. Considering 
the difference in infiltrating Foxp3+ cells observed in the tissue sections, mRNA expression in 
the liver of recipients with functional grafts was assessed at 100 days. No significant difference 
between mice treated with MSCs, CTLA4Ig and anti-CD40L, compared to only CTLA4Ig and 
anti-CD40L, could be established. 
 
4.1.5 The addition of MSCs to costimulation blockade attenuates lymphocyte 
proliferation (Paper II) 
MLR was performed 30 and 100 days after the transplantation of allogeneic Balb/C islets to 
C57bl/6 mice. Irradiated splenocytes from the donor mice were co-cultured with splenocytes 
from the recipient mice of the different treatment groups. Proliferation was measured using 
[3H] thymidine incorporation. One-hundred days post-transplantation, the proliferation induced 
by donor antigen in mice treated with MSCs, CTLA4Ig and anti-CD40L was similar to that of 
naïve mice and significantly lower compared to mice given CTLA4Ig and anti-CD40L (Fig. 
8). 
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Figure 7. (A) shows the percentage of graft survival in mice transplanted with allogeneic islets. 
The differences between groups were tested using log-rank statistics. *, p < 0.05: MSC+ 
CTLA4Ig + anti-CD40L vs. CTLA4Ig + anti-CD40L; **, p < 0.05: MSC + CTLA4Ig + anti-
CD40L vs. CTLA4Ig. (B) depicts the results from the intraperitoneal glucose tolerance test 4 
weeks after transplantation. Non-transplanted age-matched C57BL/6 naïve mice were tested 
simultaneously. Data are shown as mean ± SD. *, p < 0.05: MSC + CTLA4Ig + anti-CD40L 
vs. CTLA4Ig + anti-CD40L; #, p < 0.05: MSC + CTLA4Ig + anti-CD40L vs. CTLA4Ig; $, p 
<0.05: naïve vs. CTLA4Ig; +, p <0.05: naïve vs. CTLA4Ig + anti-CD40L. Statistical analysis 
was performed by analysis of variance with the Tukey-Kramer post hoc test, n = 5–9. 
 
 
 
Figure 8. The suppression of T cells’ proliferative response at 30 days and 100 days in 
allogeneic islet recipients. The suppressive effect was assessed using a mixed lymphocyte 
reaction wherein splenocytes from C57BL/6 recipients were co-cultured with Balb/C 
splenocytes at 4 days and the proliferation was measured by [3H] thymidine incorporation. The 
results are shown as a percentage of the response calculated from the mean cpm of the 
allogeneic reaction after the subtraction of the mean syngeneic response in each group divided 
by that of naïve mice in each experiment *, p < 0.05; **, p < 0.01.  
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4.2 PAPER III AND IV – ENGRAFTMENT 
 
4.2.1 Human fetal cardiac MSCs cultured in 2D express aSMA and low levels 
of CD31 (Paper III) 
Human fetal cardiac MSCs (hfcMSCs) are MSCs originating from the mesenchymal fraction 
of the fetal heart. These cells can be efficiently expanded in a culture and fulfill the ISCT 
criteria of being MSCs.59 The hfcMSCs are multipotent and can be differentiated into 
endothelial cells, smooth muscle cells and, to a minor extent, spontaneously beating 
cardiomyocytes.59 Considering their origin and plasticity, hfcMSCs have the potential to serve 
as optimal cells for cellular therapy aiming to restore heart function.  
In the preparation for the in vivo experiments, the hfcMSCs were expanded in 2D cultures. The 
aSMA expression was found to be high, with an eight-fold increase in mRNA when compared 
to Human Carotid Artery Smooth Muscle Cells (HCtASMCs), and CD31 expression was 
limited, with mRNA levels 500 times lower than in Human Aortic Endothelial Cells (HAEC). 
Troponin T was barely detectable at the mRNA level and immunohistochemistry yielded no 
positive cells. The immune stainings for aSMA showed ubiquitous expression, whereas CD31+ 
cells were few in numbers, agreeing with the mRNA findings.  
 
4.2.2 hfcMSCs survive and proliferate on NT2RepCT (Paper IV) 
Since we wanted to explore NT2RepCT as a scaffold for in vivo implantation we needed to 
assess whether NT2RepCT is able to support cell culture. The hfcMSCs were cultured in 2D 
on dishes coated with NT2RepCT, Geltrex (a Matrigel-like coating normally used for hfcMSCs 
cultures) or no coating (plastic). No difference was found in the cell survival or proliferation of 
hfcMSCs depending on the coating of the culture dishes, establishing NT2RepCT as suitable 
to support hfcMSC culture.  
 
4.2.3 hfcMSCs cultured in 3D form tubular structures and express basal 
membrane components (Paper III and IV) 
To simulate the in vivo situation, 3D cultures with Matrigel and hfcMSCs were generated. Even 
though the hfcMSCs formed tubular structures, the expression of CD31, as judged by 
immunohistochemistry, was low and aSMA dominated. NT2RepCT fibers could be modeled 
into 3D scaffolds that seemed suitable for implantation. To prepare for the in vivo studies we 
first tested whether NT2RepCT scaffolds may support 3D cultures. The hfcMSCs were seeded 
on top of an NT2RepCT 3D scaffold and the cultures were analyzed at 2, 4, 6 and 8 weeks. We 
found that hfcMSCs survived for at least 8 weeks and attached to the NT2RepCT fibers through 
vinculin. As observed earlier, aSMA was the most prominent staining, but CD31+ cells were 
also observed. The H&E stainings demonstrated that the hfcMSCs produced their own ECM, 
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embedding the NT2RepCT fibers. Immunohistochemical stainings indicated that the hfcMSCs 
produced the basement membrane proteins perlecan, laminin a4 and g1 as well as collagen IV. 
 
4.2.4 Vessel-like structures are present in 3D cultures of hfcMSCs and 
NT2RepCT (Paper IV) 
Considering the in vitro capacity of hfcMSCs to differentiate into endothelial cells59 and the 
tubular formation observed in Matrigel 3D cultures, we wanted to investigate the vasculogenic 
potential of hfcMSCs when cultured on NT2RepCT scaffolds. We found that hfcMSCs seeded 
onto NT2RepCT scaffolds formed vessel-like structures if supplied with endothelial 
differentiation medium. Compared to 3D cultures that received basal medium (DMEM/F12 
supplied with 2% FBS and B27), the number of CD31+ cells significantly increased (Fig. 9A). 
We also found that cell density was enhanced (Fig. 9B) and aSMA and CD31 (Fig. 9C) were 
abundantly expressed along with laminin a4 (Fig. 9D) and fibronectin (Fig. 9E), with the latter 
two being important components making up the ECM of the vessel wall.150 The vessel-like 
structures observed expressed laminin a4 (Fig. 9D) or CD31.  
 
 
Figure 9. 3D cultures with hfcMSCs on NT2RepCT scaffolds were analyzed with the use of 
immunohistochemistry after 2 weeks in the culture. The basal medium (control) was compared 
to a culture in endothelial differentiation medium (EC) regarding the number of CD31+ cells, 
which is depicted in the bar graph (A). ***P <0.0001. (B–E) are images of tissue sections from 
3D cultures grown in endothelial differentiation medium. H&E was used to visualize the ECM 
formation in relation to the NT2RepCT fibers of the scaffold, which are indicated by the arrows 
in (B). An immune staining for CD31 (AF488, green) is shown in (C), where positive cells are 
indicated by arrows. Representative vessel-like structures are shown in (D), here surrounded 
by Laminin a4 (AF488), where the inset is a magnification of the structure indicated by the 
arrow. (E) shows an immune staining for fibronectin (AF488). All images (C–E) are merged 
from microphotographs taken with 546 (red), 488 (green) and DAPI filters. The red appearance 
of NT2RepCT fibers is due to autofluorescence. The nuclei were stained with DAPI. Scale bars 
= 60 µm (B, C), 30 µm (D), 10 µm (E). 
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4.2.5 hfcMSCs are retained subcutaneously in mice treated with 
costimulation blockade (Paper III and IV) 
Immunocompetent NMRI mice were transplanted with hfcMSCs subcutaneously and treated 
with CTLA4Ig, anti-CD40L and anti-LFA-1 (costimulation blockade) to avoid rejection. The 
control group received isotype control antibodies. The in vivo experiment in study III was 
performed using Matrigel as the delivery matrix, which was compared to cell delivery in only 
the culture medium (DMEM/F12). The NMRI mice treated with costimulation blockade and 
hfcMSCs in Matrigel displayed retaining cells at 4 weeks in 8 out of 8 mice (Fig. 10 A and E), 
while costimulation blockade and DMEM/F12 yielded retaining cells at 4 weeks in 2 out of 3 
mice (Fig. 10 D and H). The number of retaining human cells per tissue section was increased 
if Matrigel was used for delivery, as compared to DMEM/F12 (Fig. 10 N). The hfcMSCs were 
not found at 4 weeks when the NMRI mice were treated with isotype control antibodies.  
The in vivo experiment performed in study IV concerned the transplantation of hfcMSC 3D 
cultures on NT2RepCT scaffolds. The cells were allowed 12 days to establish 3D cultures on 
the NT2RepCT scaffolds prior to implantation. At 4 weeks, 3 out of 3 NMRI mice treated with 
costimulation blockade exhibited surviving human cells (Fig. 12 A and C). The NMRI mice 
treated with isotype control antibodies displayed occasional human cells in 3 out of 6 animals 
at 4 weeks (Fig. 12 B and D), but costimulation blockade significantly increased cell survival. 
Three mice treated with costimulation blockade were kept for 8 weeks, but at that time point 
no surviving human cells were identified. 
4.2.6 The hfcMSCs delivered in Matrigel are rejected after 8 to 12 weeks 
(Paper III) 
Additional groups of NMRI mice, treated with costimulation blockade and implanted with 
hfcMSCs in Matrigel, were kept for 8 and 12 weeks to assess whether the immunological 
tolerance of hfcMSCs was persistent. At 8 weeks, 2 out of 6 mice still displayed retaining cells 
(Fig. 10 B and F). At 12 weeks, human cells were not found in any of the 6 mice kept until this 
time point (Fig. 10 C, G and M). At 4 weeks, CD4+ or CD8+ cells were not found surrounding 
or infiltrating the implant (Fig 10 I and L), however at 8 weeks and 12 weeks the surviving 
cells or Matrigel residues were surrounded by an immune reaction dominated by CD4+ T cells 
(Fig. 10 J and K). CD8+ and Foxp3+ T cells were present but scarce. The few Foxp3+ cells 
present were not located close to the graft, as was found in a previous experiment.  
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Figure 10. Tissue sections from NMRI mice treated with costimulation blockade (A–L) were 
stained with H&E (A–D) to visualize the area of implantation, analyzed with FISH (E–H) to 
assess whether human cells (SpectrumRed) were present and stained with antibodies against 
CD4 (I–L), AF488 (green), to assess the immunologic rejection. Scale bar = 100 µm. (M) 
shows the percentage of graft survival over time, in mice implanted with hfcMSCs in Matrigel. 
(N) is a dot plot visualizing the increased engraftment obtained with Matrigel instead of 
DMEM/F12 for mice treated with costimulation blockade. ***P < 0.0001. DMEM; 
DMEM/F12, hDNA; human DNA. 
 
 
 
 
 
  29 
4.2.7 hfcMSCs form vessel-like structures in vivo, expressing CD31 and 
laminin a4 (Paper III) 
As a delivery matrix, Matrigel consistently resulted in hfcMSC grafts at 4 weeks and these 
grafts were further characterized. H&E indicated the formation of vessel-like structures, which 
stained positive for laminin a4 or CD31. aSMA was found in areas of close proximity. 
Immunohistochemistry combined with FISH revealed CD31 and laminin a4 located 
exclusively close to human cells (Fig. 11 A-D), indicating that these proteins were expressed 
by hfcMSCs. aSMA was found near both human cells and mouse cells. The hfcMSCs 
delivered in DMEM/F12 did not express CD31, laminin a4 or aSMA.  
 
Figure 11. hfcMSCs re-suspended in Matrigel were transplanted to NMRI mice treated with 
costimulation blockade. FISH was used to assess the presence of cells containing human DNA 
(SpectrumRed). Immunohistochemistry for CD31 (A, C) and laminin a4 (B, D), both AF488 
(green), was applied subsequently to FISH. The arrows indicate the structures magnified in the 
inset. (A, B) and (C, D) are sections of close proximity. Scale bar: 50 µm. LAMA4; laminin 
a4. 
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4.2.8 NT2RepCT 3D scaffolds are immunogenic (Paper IV) 
The hfcMSCs on the NT2RepCT scaffolds were surrounded by an immunologic reaction 
already at 4 weeks post-implantation (Fig. 12 E and F). The CD4+ T cells dominated, but CD8+ 
T cells were also present as well as occasional Foxp3+ cells. Animals treated with isotype 
control antibodies displayed a similar immune reaction; however, very few human cells were 
present. A control group consisting of NMRI mice that received no antibody treatment were 
implanted with naked NT2RepCT scaffolds. These scaffolds were surrounded by a more 
intense immune reaction than the one observed in animals implanted with 3D cultures attached 
to the NT2RepCT scaffolds. Since NT2RepCT is produced in E-coli, we hypothesized that 
lipopolysaccharides (LPS) originating from the bacteria may be the cause of this observation. 
In order to solve this problem, different strategies were used wherein NT2RepCT was more 
extensively washed to remove the LPS, or produced in clear coli, bacteria with defective LPS. 
At 4 weeks, the NT2RepCT still induced an immunologic response in the subcutaneous tissue 
of NMRI mice, where both CD4+ and CD8+ T cells were present. The immune response was 
similar to that observed after the implantation of the original NT2RepCT fibers.  
 
Figure 12. hfcMSC 3D cultures on NT2RepCT were implanted subcutaneously in mice and 
analyzed after 4 weeks. (A, C, E) show tissue sections from mice treated with costimulation 
blockade and (B, D, F) show tissue sections from mice treated with isotype control antibodies. 
H&E (A, B) gave an overview of the tissue and verified the presence of NT2RepCT fibers, 
staining bright pink. FISH (C, D) identified surviving human cells when they were present 
(SpectrumRed). Immunohistochemistry for CD4 (E, F), AF488 (green), was applied to assess 
the presence of lymphocytes. Scale bar = 50 µm (C, D), 100µm (A, B, E, F). hDNA; human 
DNA. 
 
 
  
  31 
5 GENERAL DISCUSSION 
 
Immune rejection and anoikis constitute substantial impediments to the successful 
transplantation of cellular grafts. By addressing these two factors simultaneously, we have 
demonstrated their synergistic effects on engraftment in different animal models, which was 
an overall aim of this thesis. Three different cell types have been used for transplantation 
studies: HESCs, hfcMSCs and insulin-producing pancreatic islets. Previously both MSCs and 
HESCs have been attributed an immune privileged status, even when used for 
xenotransplantation, but this notion was later questioned.151-153 The synthesis of immuno-
modulatory molecules by MSCs may potentially contribute to a reduced local inflammation; 
however, they do not escape immunologic recognition.153 The absence of MHC class II and 
costimulatory molecules, a feature often suggested to support immune privilege,154 only 
indicate that these cells are not functional APCs. Antigens derived from MSCs and HESCs 
may still be presented to T cells by host APCs and initiate a specific immune response. 
 
5.1 REGULATORY T CELLS MEDIATE GRAFT ACCEPTANCE AFTER 
TREATMENT WITH TRANSIENT COSTIMULATION BLOCKADE  
 
A transient blockade of the T cell costimulation has been shown to prevent immune rejection 
in immunologically competent mice receiving various allografts and xenografts.142-144,155 
Theoretically, the acceptance could be due to the generation of specific Tregs, which is 
supported by the presence of intragraft T cells in cardiac allografts.155 In Paper I and II, Foxp3+ 
Tregs were shown to infiltrate allografts in the liver as well as surrounding the xenografts in 
the kidney when costimulation blockade was used to avoid immune rejection. These findings 
further support a central role for Tregs in costimulation-blockade-mediated immunologic 
acceptance or tolerance. In Paper III, the immunomodulatory effect of costimulation blockade 
was further challenged by transplanting hfcMSCs to the subcutis of immunocompetent NMRI 
mice. Grafts were found at 4 weeks, but there were no Tregs in the vicinity. These xenografts 
were rejected at 8 to 12 weeks. The skin and subcutis are more immunologically active tissues 
containing numerous APCs, making it harder to achieve persistent acceptance here, as 
compared to other tissues.155 The lack of Tregs around the subcutaneous grafts and subsequent 
rejection show that tolerance was not obtained in this model and further support that immune 
tolerance induced by costimulation blockade, in contrast to a prolonged acceptance, is mediated 
through Tregs.  
The skin forms a border between the organism and the outer world and is considered a more 
stringent immunological environment containing more APCs and is also known to be more 
challenging for transplantation156 than, for example, the kidney or heart. Furthermore, it might 
be speculated that pro-inflammatory cytokines produced by the local APCs of the skin reduce 
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both the formation and stability of Tregs. This could account for the lack of Tregs surrounding 
the human grafts in the subcutis. Treg instability has been shown for in vitro-induced Tregs, 
which may lose their Foxp3 expression, due to the increased methylation of the Foxp3 gene, 
compared to thymic Tregs.157 In vivo-generated peripheral Tregs have exhibited a more stable 
Foxp3 expression with an epigenetic modulation similar to that of thymic Tregs.41,157 It is 
possible that Tregs formed in mice treated with costimulation blockade initially display an 
increased methylation status. Over time the Foxp3 expression could potentially be more stably 
expressed in the kidney and liver, but perhaps this does not occur in the immunologically more 
stringent environment of the skin.  
It is important to stress that we cannot rule out the rejection of HESCs and islets at a later time 
point than the one chosen for the studies described in Paper I and II. For the insulin-producing 
islets transplanted to the liver of allogeneic mice, the decrease in insulin mRNA may indicate 
the onset of rejection. However, the MLR showed similar T cell reactivity to the allogeneic 
antigen for transplanted mice as for naïve mice, which instead speaks in favor of long-lasting 
tolerance.  
Another aspect to consider is that the mouse model is not optimal to prove persistent tolerance 
induction since mice have a short life-span. Even prolonged studies of these animals would be 
inconclusive, since any therapy applicable to humans would need to induce a tolerance lasting 
for years or decades. 
 
5.2 HESCS ARE REJECTED BY IMMUNOCOMPROMISED SCID/BEIGE MICE 
 
The HESCs transplanted to immunocompetent mice were subjected to immune rejection, 
which could be prevented when the costimulation of T cells was blocked. The HESCs 
transplanted to the kidney capsule of NSG mice formed a teratoma without the need for any 
immunomodulation. However, the HESCs transplanted to Scid/beige mice did not survive, 
regardless of costimulation blockade treatment. Scid/beige mice are immunodeficient and lack 
a functional adaptive immune response; however, in contrast to NSG mice, they do have NK 
cell function.148 NK cells may act in xenograft rejection since they recognize MHC class I 
deficient cells. Foreign MHC class I may not register in a xenogeneic environment, rendering 
the transplanted cells susceptible to NK cell-mediated destruction. In the case of Scid/beige 
mice, we cannot expect costimulation blockade to make a difference in terms of cell 
engraftment, since the mechanism behind costimulation-blockade-mediated 
immunomodulation depends on a functional adaptive immune response. The lack of Treg 
formation in Scid/beige mice likely accounts for the observed HESC graft acceptance in 
immunocompetent mice treated with costimulation blockade, but not in immunodeficient 
Scid/beige mice. The immunocompetent mice may of course mount a NK cell response as well, 
but the induction of Tregs, presumably due to costimulation blockade treatment, may dampen 
the NK cell function. The NSG mice that consistently accepted HESCs lack functional NK 
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cells,158 which supports the theory that NK cells are the main reason behind the higher 
acceptance of HESC in immunocompetent mice with costimulation blockade than in 
Scid/beige mice. 
 
5.3 IMMUNOLOGICAL LIMITATIONS 
 
Preclinical models utilizing small animals are vital to research and can optimize the use of large 
animals, such as non-human primates, without increased risk for future patients. However, a 
mouse model used for immunological studies has several limitations. From an evolutionary 
perspective, the adaptive immune system developed initially in vertebrates and is therefore a 
relatively “new” function. It has been the subject of great evolutionary pressure since humans 
started living in larger communities, with greater potential for the spread of bacterial and viral 
disease. Perhaps this is part of the explanation for the autoimmune diseases that afflict humans 
today.  
Whereas many other organs are similar in mice and humans, major differences between mouse 
and human immunology also exist, one example being the accumulation of CD28- T cells in 
human adults.127 Even non-human primates differ substantially from humans, as exemplified 
by a phase 1 drug trial performed in 2006 with a CD28 superagonist (TGN1412).159 An 
orthologous antibody had previously been successfully tested in small-animal models of 
autoimmune disease160 and subsequently, TGN1412 had been tested in non-human primates 
without adverse events.161 However, when the substance was administered to six healthy 
human volunteers, they became critically ill due to a cytokine storm and developed organ 
failure, demanding hospitalization. Evolutionary pressure may explain the great difference 
between species regarding the immune system and may also indicate large individual variances 
in the population, further complicating matters.  
Further limitations connected to the use of mice include their limited exposure to antigens in 
general, which is due to a short life span combined with the clean conditions of an animal 
facility. This limited antigen exposure will reduce the risk of preformed memory immune cells 
directed to donor-derived antigens, which may facilitate the immune acceptance of transplants. 
Transplantation is a very special immunologic situation, wherein a large number of cells from 
the donor is delivered to the recipient. This results in a an extremely high amount of donor-
derived antigen becoming available to the immune system. The amount of antigen present 
shortly after a transplantation would seldom be observed in nature and may override the 
requirement of costimulation for T cell activation in certain T cell subsets. CD28 stimulation 
is generally needed for an adaptive immune response since it lowers the threshold for T cell 
activation after antigen exposure. However, for memory T cells, this threshold is lower to begin 
with.162 The overload of antigen derived from the transplant in the period after transplantation 
could prove to be sufficient on its own for the activation of pre-existing memory T cells, 
rendering costimulation blockade ineffective. In comparison to humans, the absence of relevant 
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memory T cells as well as the differential CD28 expression in mice127 render the discrepancy 
in results between a mouse model and a human model with costimulation blockade significant. 
Although mouse models have several drawbacks, they are still extremely valuable in serving 
as the first in vivo model to test a concept derived from in vitro experiments.  
 
5.4 SYNERGISTIC EFFECTS OF COSTIMULATION BLOCKADE COMBINED 
WITH MSCS OR MATRIGEL FOR ENHANCED CELL RETENTION 
 
As the delivery matrix, Matrigel provided increased survival of human cells in a xenogeneic 
environment, if combined with costimulation blockade treatment. Matrigel alone did not 
improve cell engraftment and costimulation blockade alone provided significantly smaller 
grafts. The synergistic effect observed is likely a combination of reduced anoikis during the 
first days after the delivery due to the presence of Matrigel, and prolonged survival due to 
immune-modulation mediated by the costimulation-blocking antibodies.  
When allogeneic insulin-producing islets were transplanted to the liver in mice, we observed a 
synergy between costimulation blockade and MSCs. Only mice treated with MSCs in 
combination with costimulation blockade demonstrated long-term acceptance of allogeneic 
islets and also retained similar glucose levels to those of healthy mice. As demonstrated by 
MLR, these mice also showed the same reactivity toward allogeneic antigens as naïve mice. 
The synergistic effect observed between MSCs and costimulation blockade treatment could 
potentially be ascribed to a dual effect on the immune response, wherein the MSCs may act 
through the modulation of innate pathways and the costimulation blockade regulates the 
adaptive response. Mice that were given islets combined with the administration of MSCs and 
no additional immunomodulation displayed the same poor islet survival as control animals. 
However, the findings from the MLR indicated a reduced reactivity toward allogeneic antigens 
by mice treated with only MSCs as compared to control animals, even though the islets did not 
engraft. Another potential mechanism is that MSCs decrease anoikis by providing paracrine 
signals leading to decreased apoptosis, while costimulation blockade decreases immune 
rejection. An earlier study focused on the trophic effects of MSCs, showing that they can aid 
in the engraftment of islets in mice.163 The mechanism proposed depended on the presence of 
antiapoptotic and proangiogenic factors produced by MSCs. It is reasonable to assume that the 
positive effects observed when transplanting islets together with MSCs could involve both 
immunologic and anti-apoptotic mechanisms. The MSCs may reduce anoikis by providing 
ECM factors that are vital for anchorage and perhaps also cell–cell interactions. The acute 
inflammatory reaction occurring after delivery into a new tissue could be attenuated earlier by 
the MSCs’ ability to affect the DCs in the vicinity and in this way induce a tolerogenic profile.36 
These results indicate that autologous MSCs may increase the potential of other immune 
modulatory therapies used in organ or cell transplantation. 
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5.5 VASCULOGENIC POTENTIAL OF HUMAN FETAL CARDIAC MSCS 
 
The hfcMSCs were studied in a xenogeneic model where long-term survival was not achieved. 
However, in the case of MSCs as a potential cell therapy for heart disease, long-term survival 
is not required since the paracrine factors contributing to a positive tissue homeostasis 
constitute their proposed mode of action. After a myocardial infarction, the original ECM is 
altered and the new ECM has been shown to contain an increased proportion of Collagen I, 
while laminins almost disappear and fibronectin content is decreased.164 This will result in 
increased tissue stiffness, which may contribute to preventing the rupture of the ventricle wall 
at the price of lost contractile function and the risk of re-entry ventricular arrhythmias.  
In Paper III, we observed that the hfcMSCs formed vessel-like structures expressing CD31 and 
also that they deposited laminin a4 in vivo. In Paper IV, we found that in vitro 3D cultures of 
hfcMSCs on NT2RepCT cultured in an endothelial differentiation medium were able to form 
CD31+ vessel-like structures, resembling what they did in vivo. The cells could also deposit 
laminin a4 and fibronectin, further supporting their ability to contribute ECM components of 
relevance after a myocardial infarction. Fibronectin and laminin a4 are important parts of the 
vascular basement membrane.150 Therefore, the presence of these proteins along with CD31+ 
hfcMSCs support the vasculogenic potential of these cells. Since the lack of laminin a4 has 
been implicated in heart failure in a mouse model,69 the repeated findings that hfcMSCs deposit 
this laminin chain both in vitro and in vivo could be important when considering hfcMSCs as 
a potential treatment for heart failure. The results presented here indicate that hfcMSCs may 
have potential for use in cell therapy aiming to treat heart disease. Unpublished results show 
that Matrigel and costimulation blockade aid in the survival of hfcMSCs in the heart muscle as 
well, but further studies to assess the functional effects are needed to evaluate whether this kind 
of treatment may be effective. 
A prolonged retention of the transplanted cells for up to a few weeks or months may be 
sufficient to break a vicious cycle of inflammation and stimulate angiogenesis or other positive 
regenerative effects in the tissue. For this purpose, we have shown that short-term costimulation 
blockade was sufficient to keep the implanted hfcMSCs in our subcutaneous animal model. 
However, the immune rejection observed in the subcutis at 8 to 12 weeks would be deleterious 
if it took place in the heart muscle. Our unpublished data show that hfcMSCs delivered in 
Matrigel are present at 4 weeks but not at 8 weeks after transplantation to the heart of NMRI 
mice treated with costimulation blockade. In the heart, which is not as immunologically 
stringent as the subcutis, signs of immune rejection with lymphocyte infiltration were not 
observed at 4 or 8 weeks. Due to the dynamic mechanical environment the cardiac tissue poses 
a challenge in terms of successful cell anchorage after transplantation and co-transplanted 
Matrigel is likely not enough to fully counteract anoikis in this model. 
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5.6 ARTIFICIAL SPIDER SILK SUPPORTS 3D CULTURES 
 
Traditionally, cells have been cultured in 2D and passaged to a new culture plate when they are 
confluent. This is practical, but the reduced complexity of a 2D model will only reflect cellular 
processes, like morphogenesis, to a limited degree.165 The ECM produced will also be disrupted 
whenever cells are passaged. Matrigel and decellularized ECM are two examples of materials 
used successfully for 3D cultures.166,167 This culture technique supports long-term in vitro 
studies allowing cellular bonds that resemble those found in native tissue in terms of spatial 
distribution, and ECM can be synthesized over time without the problem of over-confluency. 
The transplantation of 3D cultures might also have a positive impact on cell survival after 
implantation since cell–cell connections and cell–ECM interactions are preserved in the 
structure. When Matrigel or decellularized ECM support 3D cultures, they provide a wide 
variety of complex ECM molecules to the culture. Artificial spider silk, on the other hand, 
merely provides a physical scaffold without any pre-existing ECM components present, which 
differs from the previously mentioned matrix structures.  
In Paper IV, hfcMSCs were shown to readily attach to a scaffold composed of a new kind of 
artificial spider silk fiber, NT2RepCT. The cells formed connections to the NT2RepCT fibers 
through vinculin, indicating the formation of focal adhesions between the fibers and 
hfcMSCs.168 The hfcMSCs formed an ECM containing collagen IV, laminins and perlecan, the 
essential components of basal membranes.79 This culture method seemed promising as a means 
to provide support and in this way increase cell survival after transplantation. Unfortunately, 
we found that NT2RepCT, with or without hfcMSC 3D cultures attached, was not 
immunologically inert, as was reported to be the case for spider silk proteins in general.95,169 
Rejection was apparent at 4 weeks also in animals treated with costimulation blockade. 
Attempts to remove LPS through additional washing steps and production in bacteria with 
defective LPS (clear coli) did not decrease the immune response. When NT2RepCT scaffolds 
were transplanted alone, without hfcMSC attached to the fibers, we observed a more intense 
immune reaction than that directed to the transplanted 3D cultures, where hfcMSCs and their 
ECM components covered major parts of the fibers. From these findings, we concluded that 
bacterial residues or epitopes of NT2RepCT were the likely reason for the earlier immune 
rejection observed, as compared to hfcMSCs transplanted in Matrigel. The immune rejection 
visible around the transplanted 3D cultures at 4 weeks was similar regardless of whether the 
mice received costimulation blockade or isotype control antibodies. However, very few 
hfcMSCs survived in animals treated with isotype control antibodies, while costimulation 
blockade allowed for hfcMSC survival for 4 weeks but not 8 weeks. In previous studies, 
animals treated with isotype control antibodies very rarely displayed any surviving xenogeneic 
or allogeneic cells. In Paper IV, they were few in number, though present in three out of six 
animals, potentially due to the protective environment formed by the NT2RepCT scaffold 
covered by ECM components. 
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Transplanting a 3D structure with attached cells instead of injecting cells in single cell 
suspension may potentially enhance cell survival. Our results described in Paper IV do not 
contradict this notion, but do show that NT2RepCT is immunogenic, which overrides any 
beneficial effects. Other spider silk fibers have been reported to be immunologically inert.91,92 
The discrepancy of our results could potentially be due to the properties of the NT2RepCT 
protein, rendering it more immunogenic, or the immunogenicity of spider silk fibers in earlier 
studies failed to be recognized. Since stainings for lymphocytes have not been performed in 
previous studies of spider silk implants,92,94 it is difficult to compare our results with earlier 
publications. However, other studies have shown macrophages surrounding the spider silk, 
which could be indicative of immunogenicity.91,99 To elucidate whether it is a novel or altered 
epitope on NT2RepCT or perhaps bacterial residues that trigger the observed immune reaction, 
there are ongoing efforts to use human cells for NT2RepCT production instead of bacteria. In 
its current form, NT2RepCT cannot be used in vivo; however, it holds potential for improving 
in vitro studies where 3D cultures could be of benefit such as in, for example, toxicology 
studies. 
Decellularized scaffolds or collagens may be better candidates for the delivery of cells and 
several studies have indicated their negligible immunogenicity.166 However, it is reasonable to 
expect that the peptides contained in allogeneic or xenogeneic ECM components may be able 
to evoke an immune reaction. This expectation is further illustrated by the reactions observed 
to collagen fillers170 and the role of collagens in autoimmune disease.171 Therefore, the use of 
any 3D scaffold in transplantation has to take into account that additional antigens may 
complicate the treatment of immune rejection.  
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In conclusion, cell therapy remains a challenge and cell interaction with the new environment 
is crucial for successful engraftment. The cell selected, immunological processes involved and 
interactions with the components of the ECM will collectively affect the outcome. This thesis 
introduces a novel kind of MSC as a potential candidate for cell therapy targeting heart disease. 
Synergistic effects have also been demonstrated in terms of cell retention when anoikis and 
immune rejection are addressed simultaneously. Further knowledge about the interaction 
between cells and their ECM as well as the fundamental mechanisms controlling our immune 
system is needed for cellular therapy to serve as a future treatment option. 
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6 CONCLUSIONS 
 
 
• Foxp3+ Tregs likely mediate immunologic acceptance induced by costimulation 
blockade treatment and are found close to engrafted xenogeneic or allogeneic cells. 
  
• MSCs or Matrigel co-transplantation synergize with costimulation blockade treatment 
for the acceptance of allografts or xenografts in mice. 
 
• hfcMSCs form a vessel-like structure expressing CD31, laminin a4 and fibronectin, 
indicating vasculogenic potential. 
 
• The artificial spider silk NT2RepCT supports the 3D cell culture of hfcMSCs with the 
formation of a complex ECM. 
 
• The NT2RepCT produced in bacteria is immunogenic in vivo. 
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